Product Description
Imetelstat is a first-in-class telomerase inhibitor that could change the course of blood cancers—changing lives for the better. The development of imetelstat is grounded on Nobel Prize-winning scientific discoveries by early Geron collaborators that expanded the understanding of telomeres and telomerase and their role in the proliferation of cancer cells. Using this knowledge, Geron scientists pioneered a new approach in which oligonucleotides (short single strands of synthetic DNA or RNA) inhibit the activity of telomerase, an enzyme that helps maintain telomeres and enables the continued proliferation of malignant cells. (Sourced from: https://www.geron.com/research-and-development/imetelstat/)
Mechanisms of Action: telomerase Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Geron
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Colombia, Czech Republic, Denmark, France, Georgia, Germany, Hungary, India, Israel, Italy, Korea, Malaysia, Netherlands, Poland, Portugal, Russia, Singapore, Spain, Taiwan, Turkey, United Kingdom, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Myelodysplastic Syndrome|Myelofibrosis
Phase 2: Acute Myeloid Leukemia|Preleukemia
Phase 1: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MYF3001 | P3 |
Recruiting |
Myelofibrosis |
2026-11-25 |
|
63935937MDS3001 | P3 |
Unknown Status |
Myelodysplastic Syndrome |
2026-10-13 |
|
PEPN2312 | P1 |
Recruiting |
Acute Myelomonocytic Leukemia|Preleukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Juvenile Myelomonocytic Leukemia, |
2026-06-30 |
|
IMpress_001 | P2 |
Unknown Status |
Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2026-06-30 |